Anti-inflammatory and analgesic properties of Polyphyllin VI revealed by network pharmacology and RNA sequencing

Zhenglang Zhang,Tingting Wang,Zhenhui Luo,Muhammad Haris Zaib,Mengqin Yi,Hekun Zeng,Peiyang Li,Dan Tang,Alexei Verkhratsky,Hong Nie
DOI: https://doi.org/10.1007/s11302-023-09979-2
2023-11-22
Purinergic Signalling
Abstract:Inflammatory pain, sustained by a complex network of inflammatory mediators, is a severe and persistent illness affecting many of the general population. We explore possible anti-inflammatory pathways of Polyphyllin VI (PPVI) based on our prior study, which showed that PPVI reduces inflammation in mice to reduce pain. Network pharmacology and RNA-Seq identified the contribution of the MAPK signaling pathway to inflammatory pain. In the LPS/ATP-induced RAW264.7 cell model, pretreatment with PPVI for 1 h inhibited the release of IL-6 and IL-8, down-regulated expression of the P2X 7 receptor(P2X 7 R), and decreased phosphorylation of p38 and ERK1/2 components of the MAPK pathway. Moreover, PPVI decreased expression of IL-6 and IL-8 was observed in the serum of the inflammatory pain mice model and reduced phosphorylation of p38 and ERK1/2 in the dorsal root ganglia while the reductions of expression of IL-6 and phosphorylation of ERK1/2 were not observed after the pre-treatment with A740003 (an antagonist of the P2X 7 R). These results suggest that PPVI may inhibit the release of IL-8 by regulating P2X 7 R to reduce the phosphorylation of p38. However, the modulation of PPVI on the release of IL-6 and phosphorylation of ERK1/2 may mediated by other P2X 7 R-independent signals.
neurosciences
What problem does this paper attempt to address?